TCR diversity - a universal cancer immunotherapy biomarker? - Wikidata - awgldk - TriplyDB

TCR diversity - a universal cancer immunotherapy biomarker?

TCR diversity - a universal cancer immunotherapy biomarker?

http://www.wikidata.org/entity/Q42368649

about

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors

P2860

Q55184907-982CFE16-9B44-4200-B121-BD91C0D93ADF Q56890243-4DB7FC26-E7B8-4A70-A290-0DE1FC37654D

P2860

TCR diversity - a universal cancer immunotherapy biomarker?

http://www.wikidata.org/entity/Q42368649

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

TCR diversity - a universal cancer immunotherapy biomarker?

@en

TCR diversity - a universal cancer immunotherapy biomarker?

@nl

type

label

TCR diversity - a universal cancer immunotherapy biomarker?

@en

TCR diversity - a universal cancer immunotherapy biomarker?

@nl

prefLabel

TCR diversity - a universal cancer immunotherapy biomarker?

@en

TCR diversity - a universal cancer immunotherapy biomarker?

@nl

P1433

Q42368649-BD5FCB7B-1685-429A-BE6D-0CA2F82FF768

P1476

Q42368649-7EFE8B08-2344-434A-B160-4BBEFC369E56

P2093

Q42368649-BBEB44C0-77D8-4426-A7B1-1FECF9172CE6

P2860

Q42368649-022189FE-79B3-453F-9A5F-D8853EFF6799

Q42368649-06352274-D96B-4FDB-B1DF-F8C23C37394E

Q42368649-0C8EBD79-E0EF-4B63-91B2-DDEEFD480576

Q42368649-2E86DAC0-C775-4DCD-A043-FBEB19AFCB2A

Q42368649-306B2C60-C74B-4D98-98C9-CBB02227D4F0

Q42368649-3B20C629-4BC2-4FAB-8B13-184212AF5B8B

Q42368649-4B3AFC85-1830-49EA-A563-C662BFECD8FB

Q42368649-51FD2E5D-F2D3-4B92-AFB1-9CAB20F3701F

Q42368649-6D19B464-4ABD-4834-B3F3-61DBDE56CB50

Q42368649-8818A9AA-2F06-428B-90AE-1607A987D5B2

P2888

Q42368649-FDFE8670-0B72-4B3F-A935-6EA81F4BAB7F

P304

Q42368649-B717D80A-3EBE-4B2F-9991-A2DFB6C0B2B0

P31

Q42368649-7CF27BA2-F933-489A-921C-51F219E1E637

Q42368649-fc634331-f122-4f38-8d19-7e7ff78c68ca

P356

Q42368649-19C1A7F5-367E-428C-8158-F4DC025A7A62

P478

Q42368649-9CD8D5B8-7579-4C76-AD11-71E6BE76F866

P577

Q42368649-BC3FB22E-5BCA-423D-8261-67D8BF689FA9

P698

Q42368649-1FF3A5B2-4B75-455D-8C5F-B274DD5CF28D

P921

Q42368649-77F6F092-7724-4B6A-A9A5-C8B3A876E80D

Q42368649-C1D97CD2-A961-45AB-9022-E5862A2B9CB4

P932

Q42368649-F0A8C12B-9CB5-445F-AA26-D08A7BD1FA29

P356

S40425-016-0175-4

P1433

Journal for Immunotherapy of Cancer

P1476

TCR diversity - a universal cancer immunotherapy biomarker?

@en

P2093

Douglas G McNeel

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

PD-1 blockade induces responses by inhibiting adaptive immune resistance

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.

A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer

Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma.

P2888

s40425-016-0175-4

P304

69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-016-0175-4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27879971

http://www.w3.org/2001/XMLSchema#string

P921

P932

5109785

http://www.w3.org/2001/XMLSchema#string